Barry Bonds TRT: Legal and Disclosure Obligations Explained

What the BALCO Case Actually Alleged About Bonds's Drug Use

The Bay Area Laboratory Co-operative (BALCO) investigation, launched by federal agents in 2003, produced grand jury testimony that detailed a structured, medically supervised doping program. Victor Conte, BALCO's founder, reportedly provided athletes with a regimen that included testosterone cream, "The Clear" (tetrahydrogestrinone, or THG, a synthetic androgen undetectable at the time), human growth hormone, and insulin. Bonds's personal trainer, Greg Anderson, pleaded guilty to distributing steroids in 2005.

What THG Was and Why It Mattered Clinically

THG was a designer anabolic steroid synthesized specifically to evade existing urine screens. The FDA has never approved it for any medical use. Once the U.S. Anti-Doping Agency identified THG's structure in 2003, it was immediately scheduled as a controlled substance under the Anabolic Steroids Control Act. Research published in Drug Testing and Analysis confirmed THG binds the androgen receptor with high affinity, producing the same anabolic signaling as testosterone itself [1].

The Grand Jury Testimony Gap

Bonds testified before the grand jury that he used a substance Anderson called "flaxseed oil" and a "cream," but said he did not know they contained steroids. His 2011 obstruction conviction rested on a single "rambling" answer deemed evasive by prosecutors, not on proving he knowingly used banned drugs. The Ninth Circuit Court of Appeals reversed that conviction in 2015, and the Supreme Court declined to rehear the case in 2016.

The legal standard matters here. Federal prosecution required proving knowing possession or distribution of a Schedule III controlled substance. Medical prescribers face a parallel, if different, standard: they must document clinical indications, obtain informed consent, and comply with DEA Schedule III record-keeping rules.

The Federal Legal Framework Governing Testosterone

Testosterone is classified as a Schedule III controlled substance under the Controlled Substances Act, a classification solidified by the Anabolic Steroids Control Act of 1990 and broadened in 2004. The DEA's scheduling page for anabolic steroids confirms that all testosterone esters, including cypionate, enanthate, and propionate, fall under this schedule [2].

What Schedule III Means for Prescribers

A physician prescribing testosterone must hold an active DEA registration, issue a written prescription (no refills by phone for Schedule III after six months or five fills, whichever comes first), and maintain patient records that support a legitimate medical purpose. The phrase "legitimate medical purpose" is not vague: the FDA-approved labeling for testosterone cypionate injection restricts use to male hypogonadism confirmed by both symptoms and two morning total testosterone measurements below the laboratory reference range [3].

Prescribing testosterone to a eugonadal athlete, meaning one with normal testosterone levels, for performance enhancement falls outside the approved indication and exposes the prescriber to DEA enforcement, state medical board sanction, and potential federal prosecution under 21 U.S.C. § 843.

What Schedule III Means for Patients

Patients who obtain testosterone without a valid prescription commit a federal offense. Simple possession of a Schedule III substance carries up to one year incarceration for a first offense under 21 U.S.C. § 844. Distribution or dispensing without a valid prescription carries up to five years. Anderson's 2005 guilty plea, which included counts related to steroid distribution, illustrates exactly how these statutes apply to non-prescriber intermediaries.

TRT in Professional Baseball: The MLB Joint Drug Agreement

Major League Baseball operated with no formal drug-testing program until the 2002 collective bargaining agreement introduced a survey-testing period, and mandatory testing with consequences began only in 2004. This timing is central to understanding the Bonds allegations: the conduct BALCO documented allegedly occurred primarily between 1998 and 2003, before any enforceable MLB testing existed.

How the Joint Drug Agreement Works Now

The current MLB Joint Drug Agreement (JDA) prohibits testosterone and all other anabolic steroids without a documented Therapeutic Use Exemption (TUE). A TUE requires a diagnosis of hypogonadism supported by clinical evidence, including laboratory confirmation of low testosterone, and approval by an independent panel. The World Anti-Doping Agency's TUE criteria, which MLB references in its program design, require that the substance not produce performance enhancement beyond restoring normal physiological function [4].

First Positive-Test Penalties Under the JDA

A first positive test for testosterone currently results in an 80-game unpaid suspension. A second positive draws 162 games (one full season). A third positive triggers a lifetime ban, though the player may apply for reinstatement after two years. These penalties apply regardless of whether the athlete claims a medical need that was not pre-approved.

What a Legitimate TRT Protocol Actually Looks Like

To understand why Bonds's alleged regimen differed from therapeutic use, it helps to know what evidence-based TRT looks like. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy defines hypogonadism as a total testosterone consistently below 300 ng/dL on two separate morning measurements, accompanied by signs and symptoms such as reduced libido, fatigue, loss of lean mass, or erectile dysfunction [5].

Diagnostic Requirements

Two fasting morning total testosterone levels below 300 ng/dL are required before initiating therapy. Measurement should occur by liquid chromatography-tandem mass spectrometry (LC-MS/MS), the most accurate method available, rather than immunoassay alone. A 2017 analysis in the Journal of Clinical Endocrinology and Metabolism found immunoassay methods overestimate testosterone by up to 15% in samples below 300 ng/dL, which can lead to under-diagnosis [6].

Approved Formulations and Doses

FDA-approved testosterone formulations for hypogonadism include:

• Testosterone cypionate or enanthate injection: 50 to 200 mg intramuscularly every 1 to 2 weeks, or 100 mg weekly to reduce peak-trough swings.
• Testosterone undecanoate injection (Aveed): 750 mg IM at baseline, week 4, then every 10 weeks.
• Transdermal gel (AndroGel 1.62%, Testim, Vogelxo): 20.25 to 81 mg applied daily.
• Transdermal cream: Compounded preparations exist but lack FDA approval; their use in the BALCO context is telling, as custom formulations are harder to detect and trace.

The therapeutic goal is a mid-normal total testosterone of 400 to 700 ng/dL, not supraphysiologic levels of 1,000 to 3,000 ng/dL that would be associated with performance-enhancing dosing.

Monitoring Obligations

The Endocrine Society guideline specifies that clinicians must check total testosterone 3 to 6 months after initiation and then annually, measure hematocrit at baseline and every 3 to 6 months (withholding therapy if hematocrit exceeds 54%), and assess bone density, lipid panel, and PSA according to age-appropriate schedules [5]. None of these monitoring obligations appear to have been part of the BALCO regimen, which was not designed for patient safety.

HGH: A Separate Legal and Clinical Category

Human growth hormone entered the Bonds allegations alongside testosterone. HGH is not an anabolic steroid and is not scheduled under the Controlled Substances Act. It is, however, a prescription drug regulated by the FDA under 21 U.S.C. § 333(e), which specifically prohibits distribution or possession of HGH for any purpose other than the treatment of a disease or condition listed on the FDA-approved label.

FDA-Approved Indications for HGH

The FDA prescribing information for somatropin (Genotropin, Humatrope, Norditropin, and others) approves use in adults only for growth hormone deficiency confirmed by stimulation testing, short bowel syndrome, or AIDS-related wasting [7]. Athletic performance enhancement is not an approved indication. Knowingly distributing HGH for unapproved performance uses is a federal felony carrying up to five years imprisonment under 21 U.S.C. § 333(e)(1).

Why HGH Testing Lagged

Blood-based HGH testing was not reliable enough for use in anti-doping programs until the mid-2000s. MLB did not implement HGH blood testing until 2012 for in-season testing and 2014 for spring training. The lag between illicit use and detection capacity is precisely why the BALCO network operated as long as it did.

Disclosure Obligations: What Athletes and Prescribers Must Do

The BALCO case clarified, painfully, that informal arrangements between athletes and non-physician suppliers do not satisfy any legal disclosure standard. Here is a structured framework for understanding who must disclose what, and to whom.

Athlete Disclosure Obligations

To sports governing bodies: Any athlete subject to WADA or a WADA-aligned program (including MLB, NFL, NBA, and USADA-governed Olympic sports) must disclose all medications on their TUE application before use begins. Retroactive TUE applications are permitted only in emergency situations. Failure to obtain a TUE before a positive test voids any therapeutic defense.

To prescribers: Patients have an ethical and practical obligation to disclose sport participation to their prescribing physician so the clinician can assess TUE eligibility and avoid prescribing at doses that would fail a drug test. Patients who conceal sport participation and later test positive cannot use their prescription as a mitigating defense under most JDA or WADA rules.

To insurers: Testosterone for hypogonadism is a covered benefit under most commercial plans when documented criteria are met. Misrepresenting the indication (claiming hypogonadism when the prescription is for performance) constitutes insurance fraud.

Prescriber Disclosure Obligations

DEA reporting: Prescribers must report any theft or significant loss of Schedule III substances to the DEA within one business day via DEA Form 106. Routine prescribing records must be retained for at least two years.

State prescription drug monitoring programs (PDMPs): All 50 states now require Schedule III prescriptions to be reported to a PDMP within 24 to 72 hours of dispensing. Prescribers are increasingly required to query the PDMP before issuing controlled substance prescriptions. A 2022 CDC report found PDMP implementation was associated with reduced controlled-substance dispensing rates, though testosterone is rarely a drug of abuse in the traditional sense [8].

Informed consent documentation: A prescriber who fails to document that the patient was informed of Schedule III status, federal restrictions on use for performance enhancement, and potential adverse effects faces liability if the patient is later sanctioned or harmed.

Institutional Disclosure: Team Physicians

Team physicians in professional sports occupy a unique conflict-of-interest position. They serve both the athlete-patient and the employing team. The American College of Sports Medicine's position stand on the team physician notes that team physicians must place athlete health above performance and must not prescribe controlled substances outside medically indicated uses [9]. A team physician who prescribes testosterone to a eugonadal player for performance reasons violates both federal law and professional ethics standards.

Physical Evidence: What Supraphysiologic Testosterone Does to the Body

Setting aside legal questions, the clinical record of what high-dose exogenous testosterone does to healthy, eugonadal athletes is well documented. A landmark randomized trial by Bhasin et al. Published in the New England Journal of Medicine (N=43, 1996) demonstrated that 600 mg/week testosterone enanthate produced an average 6.1 kg increase in fat-free mass compared with 1.9 kg in the placebo group, without any exercise [10].

Musculoskeletal and Performance Effects

At supraphysiologic doses, testosterone accelerates muscle protein synthesis, increases satellite cell proliferation, and reduces fat mass through androgen receptor-mediated lipolysis. In a meta-analysis of 18 randomized controlled trials (Storer et al., 2003, published in JCEM), testosterone dose correlated linearly with gains in lean body mass (r = 0.73, P<0.001), confirming that the performance benefit scales with dose far above the therapeutic range [11].

Cardiovascular and Hematologic Risks

Supraphysiologic testosterone raises hematocrit, which increases blood viscosity and thrombotic risk. A 2010 trial (Basaria et al., NEJM, N=209) was stopped early after testosterone-treated men (mean age 74) showed a significantly higher rate of cardiovascular events compared with placebo, though the population was older and frailer than an elite athlete [12]. At high doses, exogenous testosterone also suppresses the hypothalamic-pituitary-gonadal axis, causing testicular atrophy and azoospermia that may persist months to years after cessation.

The Broader Policy Lesson: Why Early Testing Gaps Mattered

The 2003 federal raid on BALCO revealed that entire professional sports careers had been built, or enhanced, during a period when testing was either absent or easily defeated. MLB's survey testing in 2003 found that between 5% and 7% of players tested positive for steroids, a figure sufficient under the collective bargaining agreement to trigger mandatory testing starting in 2004. The Mitchell Report (2007), commissioned by MLB Commissioner Bud Selig, named 89 current and former players and described systemic failures in oversight [13].

The gap between the anabolic steroid epidemic in sports and the legal and testing infrastructure designed to address it is not a historical curiosity. It illustrates a consistent pattern: drug development and distribution outpace detection and regulation. THG was synthesized specifically because existing screens could not catch it. Peptide hormones, SARMs, and novel GLP-1 receptor agonist combinations currently being explored in non-medical contexts present analogous detection challenges for sports governing bodies today.

What This Means for Patients Considering TRT Today

Patients who are considering testosterone therapy outside the context of elite athletics face a far simpler legal field, but disclosure obligations still apply. A prescription from a DEA-registered physician for documented hypogonadism is lawful. Using that testosterone at doses exceeding the prescription, sharing it with another person, or obtaining it from unregistered sources remains a federal offense regardless of athletic affiliation.

For patients in any WADA-regulated sport at any level, including masters athletics, amateur cycling, and Olympic weightlifting, a TUE must be obtained before beginning therapy. The WADA prohibited list, updated annually each January 1, includes all endogenous and exogenous androgens under the S1 Anabolic Agents category [4].

Any patient with total testosterone consistently below 300 ng/dL on two morning measurements, combined with symptoms, should discuss the full TUE process with both their physician and their sport's anti-doping authority before starting treatment. The clinical case for therapy in true hypogonadism is strong. The legal and procedural requirements around it are specific and non-negotiable.